ZA200701044B - Compositions for delivering peptide YY and PYY agonists - Google Patents
Compositions for delivering peptide YY and PYY agonistsInfo
- Publication number
- ZA200701044B ZA200701044B ZA200701044A ZA200701044A ZA200701044B ZA 200701044 B ZA200701044 B ZA 200701044B ZA 200701044 A ZA200701044 A ZA 200701044A ZA 200701044 A ZA200701044 A ZA 200701044A ZA 200701044 B ZA200701044 B ZA 200701044B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- pyy agonists
- delivering peptide
- peptide
- delivering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58775104P | 2004-07-12 | 2004-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200701044B true ZA200701044B (en) | 2008-12-31 |
Family
ID=35839770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200701044A ZA200701044B (en) | 2004-07-12 | 2007-02-05 | Compositions for delivering peptide YY and PYY agonists |
Country Status (12)
Country | Link |
---|---|
US (2) | US9399054B2 (fr) |
EP (1) | EP1791553B1 (fr) |
JP (1) | JP5749879B2 (fr) |
CN (2) | CN105708787A (fr) |
AU (1) | AU2005271878B2 (fr) |
BR (1) | BRPI0513101A (fr) |
CA (1) | CA2573512C (fr) |
HK (1) | HK1107524A1 (fr) |
MX (1) | MX2007000510A (fr) |
NZ (1) | NZ552558A (fr) |
WO (1) | WO2006017251A2 (fr) |
ZA (1) | ZA200701044B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010090876A2 (fr) * | 2009-01-21 | 2010-08-12 | University Of Florida Research Foundation, Inc. | Administration d'un peptide de la satiété |
CN109157742B (zh) | 2009-08-03 | 2022-04-05 | 因卡伯实验室有限责任公司 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
US8759284B2 (en) | 2009-12-24 | 2014-06-24 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
HUE036066T2 (hu) | 2010-12-16 | 2018-06-28 | Novo Nordisk As | GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
RU2641198C3 (ru) | 2012-03-22 | 2021-12-10 | Ново Нордиск А/С | Композиции glp-1 пептидов и их получение |
AU2015267148B2 (en) | 2014-05-28 | 2021-07-29 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
AU2015331848B2 (en) | 2014-10-17 | 2022-03-03 | Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
CN108055826A (zh) * | 2015-07-02 | 2018-05-18 | 拉尼医疗有限公司 | 用于使用可吞服药物递送装置递送到肠道内腔中的治疗药剂制剂 |
ES2929758T3 (es) | 2016-05-05 | 2022-12-01 | Childrens Hospital Med Ct | Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo |
CA3045145A1 (fr) | 2016-12-05 | 2018-06-14 | Children's Hospital Medical Center | Organoides du colon et leurs procedes de preparation et d'utilisation |
WO2019139934A1 (fr) * | 2018-01-09 | 2019-07-18 | Gila Therapeutics, Inc. | Compositions et méthodes de traitement de maladies métaboliques |
CA3087733A1 (fr) | 2018-01-23 | 2019-08-01 | Gila Therapeutics, Inc. | Formulations pharmaceutiques de peptide yy, compositions et procedes |
PE20210453A1 (es) | 2018-02-02 | 2021-03-08 | Novo Nordisk As | Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante |
TWI829687B (zh) * | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
CN108947862B (zh) * | 2018-06-25 | 2020-10-16 | 上海龙灯环保科技有限公司 | 季戊四醇四((n,n-二(2-氨基乙基))-3-氨基丙酸酯)及其制备方法和应用 |
CA3126358A1 (fr) * | 2019-01-14 | 2020-07-23 | Children's Hospital Medical Center | Compositions et methodes de traitement d'un trouble de malabsorption |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151836C (zh) * | 1995-03-31 | 2004-06-02 | 艾米斯菲尔技术有限公司 | 用作传送活性剂的化合物和组合物 |
US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
US6313088B1 (en) * | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
DK0993831T3 (da) * | 1997-02-07 | 2008-03-25 | Emisphere Tech Inc | Forbindelser og præparater til tilförsel af aktive stoffer |
WO2000048589A1 (fr) * | 1999-02-22 | 2000-08-24 | Emisphere Holdings, Inc. | Forme posologique orale solide contenant de l'heparine ou un heparinoide combinee a un support |
AU4216700A (en) * | 1999-04-05 | 2000-10-23 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
WO2001032130A2 (fr) | 1999-11-05 | 2001-05-10 | Emisphere Technologies, Inc. | Composes d'acide phenylamine carboxylique et compositions permettant de distribuer des agents actifs |
JP4799794B2 (ja) * | 2000-03-21 | 2011-10-26 | エミスフェアー・テクノロジーズ・インク | ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。 |
JP2004515533A (ja) * | 2000-12-14 | 2004-05-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 代謝障害を治療するためのペプチドyyおよびペプチドyyアゴニスト |
JP4354698B2 (ja) | 2001-03-01 | 2009-10-28 | エミスフェアー・テクノロジーズ・インク | ビスホスホネートデリバリー用組成物 |
AU2002332054B2 (en) * | 2001-09-24 | 2007-11-08 | Imperial Innovations Limited | Modification of feeding behavior |
US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
EA008829B1 (ru) | 2002-12-17 | 2007-08-31 | Нэстек Фармасьютикал Кампани Инк. | Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2004104018A2 (fr) | 2003-05-14 | 2004-12-02 | Emisphere Technologies, Inc. | Compostions d'administration de peptide yy de d'agonistes pyy |
-
2005
- 2005-07-12 BR BRPI0513101-4A patent/BRPI0513101A/pt not_active Application Discontinuation
- 2005-07-12 CN CN201610087331.2A patent/CN105708787A/zh active Pending
- 2005-07-12 CA CA2573512A patent/CA2573512C/fr not_active Expired - Fee Related
- 2005-07-12 CN CNA2005800234681A patent/CN101443028A/zh active Pending
- 2005-07-12 AU AU2005271878A patent/AU2005271878B2/en not_active Ceased
- 2005-07-12 JP JP2007521549A patent/JP5749879B2/ja not_active Expired - Fee Related
- 2005-07-12 US US11/571,862 patent/US9399054B2/en active Active
- 2005-07-12 NZ NZ552558A patent/NZ552558A/en not_active IP Right Cessation
- 2005-07-12 EP EP05770299.5A patent/EP1791553B1/fr not_active Not-in-force
- 2005-07-12 WO PCT/US2005/024599 patent/WO2006017251A2/fr active Application Filing
- 2005-07-12 MX MX2007000510A patent/MX2007000510A/es active IP Right Grant
-
2007
- 2007-02-05 ZA ZA200701044A patent/ZA200701044B/xx unknown
- 2007-11-30 HK HK07113123.6A patent/HK1107524A1/xx not_active IP Right Cessation
-
2016
- 2016-06-23 US US15/190,305 patent/US20160296599A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2005271878A1 (en) | 2006-02-16 |
WO2006017251A2 (fr) | 2006-02-16 |
AU2005271878B2 (en) | 2010-02-18 |
JP5749879B2 (ja) | 2015-07-15 |
US20110183898A1 (en) | 2011-07-28 |
CN105708787A (zh) | 2016-06-29 |
BRPI0513101A (pt) | 2008-04-29 |
WO2006017251A3 (fr) | 2008-11-13 |
JP2008505973A (ja) | 2008-02-28 |
CN101443028A (zh) | 2009-05-27 |
CA2573512C (fr) | 2014-09-23 |
HK1107524A1 (en) | 2008-04-11 |
US20160296599A1 (en) | 2016-10-13 |
EP1791553A4 (fr) | 2012-09-05 |
NZ552558A (en) | 2009-11-27 |
EP1791553B1 (fr) | 2013-10-23 |
MX2007000510A (es) | 2007-03-29 |
CA2573512A1 (fr) | 2006-02-16 |
US9399054B2 (en) | 2016-07-26 |
EP1791553A2 (fr) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1107524A1 (en) | Compositions for delivering peptide yy and pyy agonists | |
ZA200508848B (en) | Compositions for delivering peptide yy and pyy agonists | |
AP2007004069A0 (en) | Pyy agonists and uses thereof | |
EP1687017A4 (fr) | Procedes et compositions permettant de distribuer des polynucleotides | |
EP1971355A4 (fr) | Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees | |
EP1756039A4 (fr) | Composes et compositions pour administration d"agents actifs | |
ZA200706030B (en) | GLP-1 agonists, compositions, methods and uses | |
PL1786272T3 (pl) | Kompozycje rozgrzewające i układy do ich dostarczania | |
IL227910A0 (en) | Flagellin-related polypeptides and uses thereof | |
IL173742A0 (en) | Compositions for delivering 5-ht agonists across the oral mucosa | |
IL180350A0 (en) | Compositions for delivering highly water soluble drugs | |
EP1773369A4 (fr) | Compositions pharmaceutiques et methodes de traitement d'un peptide | |
IL187617A0 (en) | Lkktet and/or lkktnt peptide compositions and methods | |
PL1666073T3 (pl) | Urządzenie do podawania kompozycji przeciwdrobnoustrojowej | |
IL179380A0 (en) | Compositions comprising nicotinic and opioid agonists | |
IL184266A (en) | Benzazole analogues, preparations containing them and their use as inhibitors of protein kinase | |
AU2003241313A8 (en) | Compositions and methods for stem cell delivery | |
GB0427145D0 (en) | Compositions for use in surgery | |
EP1811967A4 (fr) | Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion | |
IL186337A0 (en) | Stannsoporfin compositions and administration | |
HK1109335A1 (en) | Pharmaceutical compositions based on nk2 antagonists for pediatric use | |
EP1931327A4 (fr) | Composes cyclopropyles et compositions permettant de liberer des agents actifs | |
EP1865777A4 (fr) | Compositions de stannsoporfine et administration | |
GB0406014D0 (en) | Pharmaceutical composition and use | |
GB0413139D0 (en) | Composition and delivery system |